APRE vs. EPR

Last updated Jun 3, 2026

APRE (Aprea Therapeutics, Inc.) and EPR (EPR Properties) are both stocks. APRE operates in Biotechnology (Healthcare), while EPR operates in REIT - Retail (Real Estate). Over the past 5 years, APRE returned -61.96%/yr vs 8.75%/yr for EPR. At a 0.10 correlation, their price movements are largely independent.

Performance

APRE vs. EPR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aprea Therapeutics, Inc. (APRE) and EPR Properties (EPR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, APRE achieves a -10.41% return, which is significantly lower than EPR's 16.31% return.

APRE

• 1D: -6.34%
• 1M: -6.58%
• YTD: -10.41%
• 6M: -25.08%
• 1Y: -57.54%
• 3Y*: -40.40%
• 5Y*: -61.96%
• 10Y*: —

EPR

• 1D: 0.46%
• 1M: 2.68%
• YTD: 16.31%
• 6M: 11.49%
• 1Y: 7.69%
• 3Y*: 16.86%
• 5Y*: 8.75%
• 10Y*: 3.56%

*Multi-year figures are annualized to reflect compound growth (CAGR)

APRE vs. EPR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
APRE Aprea Therapeutics, Inc.	-10.41%	-74.07%	-30.00%	-29.00%	-88.47%	-41.67%	-89.28%	123.85%
EPR EPR Properties	16.31%	20.52%	-1.25%	38.83%	-14.61%	50.60%	-52.09%	-7.23%

Correlation

The correlation between APRE and EPR is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.07
Correlation (3Y) Calculated over the trailing 3-year period	0.09
Correlation (5Y) Calculated over the trailing 5-year period	0.13
Correlation (All Time) Calculated using the full available price history since Oct 4, 2019	0.10

Fundamentals

Market Cap APRE : $11.22M EPR : $4.32B
EPS APRE : -$1.37 EPR : $3.55
PS Ratio APRE : 56.34 EPR : 6.17
PB Ratio APRE : 0.27 EPR : 1.87
Total Revenue (TTM) APRE : $118.11K EPR : $700.22M
Gross Profit (TTM) APRE : -$1.79M EPR : $568.77M
EBITDA (TTM) APRE : -$12.56M EPR : $582.57M

Return for Risk

APRE vs. EPR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

APRE

APRE Risk / Return Rank: 13
APRE Sharpe Ratio Rank: 13
APRE Sortino Ratio Rank: 13
APRE Omega Ratio Rank: 15
APRE Calmar Ratio Rank: 11
APRE Martin Ratio Rank: 13

EPR

EPR Risk / Return Rank: 48
EPR Sharpe Ratio Rank: 52
EPR Sortino Ratio Rank: 44
EPR Omega Ratio Rank: 44
EPR Calmar Ratio Rank: 50
EPR Martin Ratio Rank: 49

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

APRE vs. EPR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Aprea Therapeutics, Inc. (APRE) and EPR Properties (EPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	APRE	EPR	Difference
Sharpe ratio Return per unit of total volatility	-0.65	0.35	-0.99
Sortino ratio Return per unit of downside risk	-0.84	0.62	-1.46
Omega ratio Gain probability vs. loss probability	0.91	1.08	-0.17
Calmar ratio Return relative to maximum drawdown	-0.78	0.43	-1.21
Martin ratio Return relative to average drawdown	-1.22	0.85	-2.07
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

APRE vs. EPR - Sharpe Ratio Comparison

The current APRE Sharpe Ratio is -0.65, which is lower than the EPR Sharpe Ratio of 0.35. The chart below compares the historical Sharpe Ratios of APRE and EPR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	APRE	EPR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.65	0.35	-0.99
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.73	0.34	-1.06
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.08	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.68	0.30	-0.98

Drawdowns

APRE vs. EPR - Drawdown Comparison

The maximum APRE drawdown since its inception was -99.94%, which is greater than EPR's maximum drawdown of -82.02%. Use the drawdown chart below to compare losses from any high point for APRE and EPR.

Drawdown Indicators

	APRE	EPR	Difference
Max Drawdown Largest peak-to-trough decline	-99.94%	-82.02%	-17.92%
Max Drawdown (1Y) Largest decline over 1 year	-71.63%	-19.51%	-52.12%
Max Drawdown (3Y) Largest decline over 3 years	-93.03%	-19.51%	-73.52%
Max Drawdown (5Y) Largest decline over 5 years	-99.48%	-35.63%	-63.85%
Max Drawdown (10Y) Largest decline over 10 years	—	-82.02%	—
Current Drawdown Current decline from peak	-99.92%	-5.08%	-94.84%
Average Drawdown Average peak-to-trough decline	-85.38%	-16.60%	-68.78%
Ulcer Index Depth and duration of drawdowns from previous peaks	45.86%	9.79%	+36.07%

Volatility

APRE vs. EPR - Volatility Comparison

Aprea Therapeutics, Inc. (APRE) has a higher volatility of 26.69% compared to EPR Properties (EPR) at 5.06%. This indicates that APRE's price experiences larger fluctuations and is considered to be riskier than EPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	APRE	EPR	Difference
Volatility (1M) Calculated over the trailing 1-month period	26.69%	5.06%	+21.63%
Volatility (6M) Calculated over the trailing 6-month period	74.88%	16.37%	+58.51%
Volatility (1Y) Calculated over the trailing 1-year period	89.36%	22.25%	+67.11%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	85.71%	26.22%	+59.49%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	89.99%	42.45%	+47.54%

Dividends

APRE vs. EPR - Dividend Comparison

APRE has not paid dividends to shareholders, while EPR's dividend yield for the trailing twelve months is around 6.35%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
APRE Aprea Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPR EPR Properties	6.35%	7.05%	7.68%	6.81%	8.62%	3.16%	4.66%	6.37%	5.62%	6.23%	5.35%	6.21%

Financials

Frequently Asked Questions

Can I hold both APRE and EPR in my portfolio?

APRE and EPR have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, APRE or EPR?

APRE has higher volatility (26.69%) compared to EPR (5.06%). In terms of maximum drawdown, APRE dropped -99.94% vs EPR's -82.02%.

Which has better risk-adjusted returns?

EPR currently has the higher Sharpe Ratio (0.35 vs -0.65), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.